Market closed

Sangamo Therapeutics/$SGMO

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Sangamo Therapeutics

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Ticker

$SGMO
Trading on

Industry

Biotechnology

Employees

405

SGMO Metrics

BasicAdvanced
$562M
Market cap
-
P/E ratio
-$1.35
EPS
1.23
Beta
-
Dividend rate
$562M
1.23
$2.68
$0.29
10M
1.027
0.727
122.824
122.824
-58.29%
-194.05%
40.85
23.73
23.73
-2.805
-94.38%
12.51%
-55.33%
12.34%

What the Analysts think about SGMO

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Sangamo Therapeutics stock.

SGMO Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SGMO Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SGMO

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Sangamo Therapeutics stock?

Sangamo Therapeutics (SGMO) has a market cap of $562M as of November 13, 2024.

What is the P/E ratio for Sangamo Therapeutics stock?

The price to earnings (P/E) ratio for Sangamo Therapeutics (SGMO) stock is 0 as of November 13, 2024.

Does Sangamo Therapeutics stock pay dividends?

No, Sangamo Therapeutics (SGMO) stock does not pay dividends to its shareholders as of November 13, 2024.

When is the next Sangamo Therapeutics dividend payment date?

Sangamo Therapeutics (SGMO) stock does not pay dividends to its shareholders.

What is the beta indicator for Sangamo Therapeutics?

Sangamo Therapeutics (SGMO) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.